CF
PACB icon

Cantor Fitzgerald’s Pacific Biosciences PACB Stock Holding History

Cantor Fitzgerald’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-275,000
Closed -$2.5M – 837
2022
Q1 		$2.5M Buy
+275,000
New +$3.17M 0.19% 123

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Cantor Fitzgerald's PACB Position: Q2 2022 in Review

Cantor Fitzgerald sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 275,000 shares — an estimated $2.5M sold.

Cantor Fitzgerald first reported a position in PACB in Q1 2022 and held it in 1 quarter. The position peaked at $2.5M in Q1 2022. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • Cantor Fitzgerald reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • Cantor Fitzgerald sold 275,000 Pacific Biosciences shares in Q2 2022, an estimated $2.5M.
  • Cantor Fitzgerald first reported a position in Pacific Biosciences in Q1 2022 and held it in 1 quarter.
  • Cantor Fitzgerald's Pacific Biosciences position peaked at $2.5M in Q1 2022.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Cantor Fitzgerald's 13F filing for Q2 2022, filed 15 Aug 2022.